Top Page
Femasys
(NASDAQ:FEMY)
Femasys (FEMY) vs. SPDR S&P 500 ETF (SPY)
Femasys Business Overview & Revenue Model
Femasys Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.63M | 1.07M | 1.21M | 1.18M | 1.04M |
| Gross Profit | 1.08M | 691.90K | 764.28K | 809.30K | 731.38K |
| EBITDA | -16.33M | -13.17M | -10.49M | -6.55M | -5.80M |
| Net Income | -18.82M | -14.25M | -11.39M | -7.54M | -6.91M |
Balance Sheet | |||||
| Total Assets | 12.45M | 27.76M | 16.90M | 28.58M | 7.61M |
| Cash, Cash Equivalents and Short-Term Investments | 3.45M | 21.72M | 12.96M | 24.78M | 3.32M |
| Total Debt | 7.44M | 6.70M | 543.72K | 990.21K | 2.06M |
| Total Liabilities | 10.14M | 9.40M | 1.65M | 2.24M | 59.42M |
| Stockholders Equity | 2.30M | 18.35M | 15.24M | 26.33M | -51.82M |
Cash Flow | |||||
| Free Cash Flow | -20.21M | -11.42M | -11.14M | -8.24M | -4.96M |
| Operating Cash Flow | -19.44M | -11.28M | -10.73M | -7.93M | -4.93M |
| Investing Cash Flow | -847.76K | -143.92K | -407.48K | -306.87K | 968.32K |
| Financing Cash Flow | 2.03M | 20.18M | -681.64K | 29.70M | 871.65K |
Femasys Technical Analysis
Femasys Risk Analysis
Femasys Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $12.13M | 1.05 | 7.10% | ― | -0.19% | -18.41% | |
60 Neutral | HK$17.39B | 5.75 | -7.44% | 3.10% | 11.55% | -28.15% | |
53 Neutral | $23.40M | ― | -138.80% | ― | -14.41% | -549.88% | |
52 Neutral | $21.66M | ― | -25.89% | ― | -16.05% | -195.28% | |
41 Neutral | $38.23M | ― | -88.36% | ― | -9.13% | 30.04% | |
40 Neutral | $28.14M | ― | -239.87% | ― | 61.97% | -6.89% | |
38 Underperform | $8.18M | ― | -504.16% | ― | -31.31% | 49.27% |
Femasys Corporate Events
On July 16, 2025, Femasys Inc. received a notice from Nasdaq indicating noncompliance with the Minimum Bid Price Requirement, as the company’s stock price had been below $1.00 for 30 consecutive business days. This notification does not immediately affect the trading of Femasys’ stock, but the company has until January 12, 2026, to meet the requirement. Femasys may consider options such as a reverse stock split to regain compliance, but there is no assurance of success.
The most recent analyst rating on (FEMY) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.
On June 30, 2025, Femasys Inc. entered into a Purchase Agreement with Alumni Capital LP, allowing the company to sell up to $10 million of its common stock over a specified period. This agreement provides Femasys with flexibility in financing, contingent on market conditions and trading prices, while ensuring compliance with regulatory requirements and ownership limitations.
The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.
On July 1, 2025, Femasys Inc. announced the achievement of regulatory approvals in Australia and New Zealand for its infertility solutions, FemaSeed for first-line intratubal insemination treatment and FemVue for diagnostic evaluation. These approvals mark a significant milestone in expanding global access to Femasys’ innovative infertility solutions, validating the clinical value of their platform and creating meaningful commercial opportunities. This development reinforces Femasys’ commitment to providing accessible, first-line infertility solutions, addressing critical gaps in care for women struggling with infertility.
The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.
On June 25, 2025, Femasys Inc. held its Annual Meeting of Stockholders, where approximately 59.41% of the total outstanding shares were represented. During the meeting, stockholders approved the election of two Class I directors, an amendment to the 2021 Equity Incentive Plan to increase authorized shares by 3,000,000, and ratified the appointment of KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.
On June 25, 2025, Femasys Inc. announced the European CE mark approval of FemBloc, the first non-surgical permanent birth control system. This approval marks a significant milestone for the company, allowing the FemBloc system to be marketed across the European Economic Area. The FemBloc system, which offers a safer and more cost-effective alternative to traditional surgical sterilization, is set to be commercially available in Spain and other select European countries. This development underscores Femasys’ commitment to providing innovative solutions in women’s health and is expected to enhance its industry positioning and impact stakeholders positively.
The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.
On June 17, 2025, Femasys Inc. announced the appointment of Kelley Nicholas as Chief Commercial Officer to lead the U.S. commercialization of fertility products and expand global partnerships. Ms. Nicholas, with over 25 years of industry experience, is expected to drive revenue growth and strengthen Femasys’ position in women’s health. The company also granted her an option to purchase 100,000 shares of common stock as an inducement for her employment.
The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.
On May 29, 2025, Femasys Inc. entered into an underwriting agreement with JonesTrading Institutional Services LLC for a public offering of 3,600,000 shares of common stock at $0.85 per share. The company also initiated a concurrent private placement with existing institutional stockholders and certain directors and officers, raising a total of approximately $4.5 million before expenses. The proceeds are intended for commercial expansion, product development, and general corporate purposes. Additionally, Femasys agreed to establish a $10 million equity line of credit with Alumni Capital LP by June 30, 2025, with potential penalties if not completed.
The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.
On May 19, 2025, Femasys received a notice from Nasdaq indicating that the market value of its listed securities had fallen below the required $35 million for continued listing on the Nasdaq Capital Market. The company has until November 17, 2025, to regain compliance, or it may face delisting. Femasys plans to actively monitor its market value and explore options to meet the requirement, although there is no assurance of success.
The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.